This is one of the biggest peptide regulatory updates in years, and it's just the beginning. The FDA has officially initiated the first step to reverse its 2023 stance, removing 12 peptides Peptides: Legal and Regulatory Risks 503A Compounding Pharmacies Must Understand Industry Update: Interim 503A and 503B Bulks Lists New Revisions Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and